

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 849 • March 2020

April 1, 2020 Full Updates for the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit Supplement (HSDBS)* and *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Please be advised that the annual April 1, 2020 Full Updates to the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit Supplement (HSDBS)* and the *Palliative Coverage Drug Benefit Supplement (PCDBS)* have been posted online at www.ab.bluecross.ca/dbl/publications.php.

Effective April 1, 2020 the following Drug Products will be removed from the *ADBL* as the Manufacturer did not submit a Price to the annual Alberta Price Confirmation process:

As per the Alberta Price Policy, Manufacturers with Drug Products currently listed on the *ADBL* were invited to re-quote the price of their Drug Product(s) for continual listing. Please be advised that the following Drug Products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective April 1, 2020 as these Manufacturers have chosen not to re-confirm their price.

All Drug Products scheduled to be removed from the *ADBL* have been identified as having therapeutic alternatives. *Effective April 1, 2020, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A 30-day transition period will be applied to allow physicians, pharmacists, and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of May 1, 2020, claims will no longer pay for these products.*

Patients impacted by the removal of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

| DIN/PIN | Product Description |
|----------|---|
| 00497193 | Aminophylline 25 mg/ml Injection |
| 02096900 | Lax-A Nema Rectal Enema |
| 00030635 | Solu-Cortef Act-O-Vial 1 g/Vial Injection |

Additionally, effective April 1, 2020, the following Drug Products will be removed from the *ADBL* as these Drug Products have been discontinued by the Manufacturer:

Notification of discontinuation has been received from the manufacturers. The Alberta government-sponsored drug programs previously covered the following Drug Products. Effective April 1, 2020, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will be applied and, as of May 1, 2020, claims will no longer pay for these products. Patients impacted by the discontinuation of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

| DIN/PIN | Product Description |
|----------|---|
| 02303442 | Accel-Pioglitazone 15 mg Tablet |
| 02303450 | Accel-Pioglitazone 30 mg Tablet |
| 02303469 | Accel-Pioglitazone 45 mg Tablet |
| 02245232 | Apo-Clindamycin 150 mg Capsule |
| 02245233 | Apo-Clindamycin 300 mg Capsule |
| 00637661 | Betagan 0.5% Ophthalmic Solution |
| 80038155 | Decaxil Vitamin D 400 IU/ml Oral Liquid |

continued on next page ...

... continued from previous page

| DIN/PIN | Product Description |
|----------|--|
| 80041145 | Decaxil Vitamin D3 400 IU Oral Drops |
| 00469327 | Demulen 30 (21 Day) Tablet |
| 00471526 | Demulen 30 (28 Day) Tablet |
| 02205963 | Dexiron 50 mg/ml Injection |
| 01919431 | Engerix-B 20 mcg/ml Injection |
| 00816086 | Folic Acid 5 mg/ml Injection |
| 02146126 | Hydromorphone HP 50 mg/ml Injection |
| 02239944 | Ketorolac Tromethamine 30 mg/ml Injection |
| 02300036 | Mylan-Enalapril 2.5 mg Tablet |
| 02300044 | Mylan-Enalapril 5 mg Tablet |
| 02300052 | Mylan-Enalapril 10 mg Tablet |
| 02300060 | Mylan-Enalapril 20 mg Tablet |
| 00757713 | pms-Cyproheptadine HCl 4 mg Tablet |
| 00664553 | pms-Docusate Calcium 240 mg Capsule |
| 00848417 | pms-Docusate Sodium 50 mg/ml Oral Syrup |
| 02282348 | pms-Fluconazole 150 mg Capsule |
| 02330105 | Ran-Fentanyl Matrix 12 mcg/hr Transdermal Patch |
| 02330113 | Ran-Fentanyl Matrix 25 mcg/hr Transdermal Patch |
| 02330148 | Ran-Fentanyl Matrix 75 mcg/hr Transdermal Patch |
| 02330156 | Ran-Fentanyl Matrix 100 mcg/hr Transdermal Patch |
| 02247691 | Sandoz Anuzinc HC Ointment |
| 02245920 | Sandoz Diltiazem T 240 mg Extended-Release Capsule |
| 02245921 | Sandoz Diltiazem T 300 mg Extended-Release Capsule |
| 02354187 | Sandoz Metoprolol (Type L) 50 mg Tablet |
| 02354195 | Sandoz Metoprolol (Type L) 100 mg Tablet |
| 02028786 | Sinemet CR 100/25 Sustained-Release Tablet |
| 00870935 | Sinemet CR 200/50 Sustained-Release Tablet |

For a summary of all updates, please refer to the April 1, 2020 Summary of Changes for highlights of products and pricing changes.

Please note that the online *Interactive Drug Benefit List (iDBL)* is available at https://www.ab.bluecross.ca/dbl/idbl_main1.php; this is a near real-time application and as such, contains the most up-to-date information.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.849 2020/03

